1[6]Manecke R G, Mulhall J P. Trends in clinical practice:medical treatment of erectile dysfunction [J]. Ann Med,1999,31:388.
2[7]Moneland R B, Nakane M, Hsieh A, et al. Prospective for pharmacotherapy of male erectile dysfunction [J]. Curr Opin CPNS Invest Drug, 2000,2(3): 283.
3[8]Fulgham P F, Cochram J S, Denman J L, et al.Disappointing initial results with transurethral alprostadil for erectile dysfunction in a urology practice setting [J]. J Urol,1998,160(6): 2 041.
4[9]Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE- 5 inhibitors sildenafil,vardenafil and tadalafil - review of the literature [J]. Eur J Med Res, 2002, 7(10): 435.
5[10]Morales A, Gingell C, Collins M, et al. Clinical safety of oral sildenafil citrate (VIAGRA) in treatment of erectile dysfunction [J]. Int J Impot Res, 1998,10(2): 69.
6[11]Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodisterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardnalil [J]. Int J Impot Res ,2001,13(5) :282.
7[12]Govier F, Potempa AJ, Kaufman J, et al. A multicenter,randomized, double - blind, crossover study of patient preference for tadalalil 20 mg or sildenafil citrate 50 mg during initiation of treatment for erectile dysfunction [J]. Clin Ther,2003, 25(11): 2 709.
8[13]Rosen RC, McKenna KE. PDE - 5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes[J]. Annu Rev Sex Res, 2002,13: 36.
9[14]Crowe SM, Streetman DS. Vardenafil treatment for erectile dysfunction[J]. Ann Pharmacother, 2004,38(1) :77.
10[15]Padma Nathan H, Stecher VJ, Sweeney M, et al. Minimal time to successful intercourse after sildenafil citrate: results of a randomized, double - blind, placebo - controlled trial [J].Urology, 2003, 62(3): 400.
